Payment overview · 2025
General Payments
$2,160.80
73 reported records · 16 companies
Healthcare provider profile · identity verified
Tin Wong, DO
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · LOS ANGELES, CA · NPI 1588927552
Verified facts
What the public records show
CMS Open Payments records show Tin Wong, DO received $2,160.80 in general payments during 2025 across 73 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Jardiance, Mounjaro, Trelegy Ellipta, Voquezna.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 331 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 331 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Paxlovid by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Voquezna by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $540.59 | 25.0% | 15 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $234.99 | 10.9% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $226.18 | 10.5% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.03 | 6.6% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $141.02 | 6.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $140.05 | 6.5% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $131.32 | 6.1% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $131.11 | 6.1% | 5 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $121.83 | 5.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $98.59 | 4.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.98 | 2.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.62 | 2.4% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $51.69 | 2.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.57 | 1.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.75 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.48 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,160.80 | 73 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $355.42 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $234.99 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $227.28 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $143.03 | 7 | 2025 |
Source payment records
|
|||||
| OverStitch Endoscopic Suturing System Normalized: overstitch endoscopic suturing system |
Device | Boston Scientific Corporation | $141.02 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $140.05 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $131.32 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $131.11 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.67 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $98.59 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $96.94 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $81.24 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $78.78 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.62 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $52.62 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $28.75 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $27.61 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 331 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 63 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
33 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | 13 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
46 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
331 | 60 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
331 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
45 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1046 | 235 |
| Amlodipine Besylate | Amlodipine Besylate | 697 | 157 |
| Losartan Potassium | Losartan Potassium | 429 | 98 |
| Zolpidem Tartrate | Zolpidem Tartrate | 362 | 65 |
| Jardiance | Empagliflozin | 331 | 60 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 318 | 92 |
| Metformin Hcl | Metformin Hcl | 310 | 67 |
| Alendronate Sodium | Alendronate Sodium | 293 | 64 |
| Lidocaine | Lidocaine | 288 | 64 |
| Icosapent Ethyl | Icosapent Ethyl | 280 | 65 |
| Montelukast Sodium | Montelukast Sodium | 277 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 65 |
| Amoxicillin | Amoxicillin | 253 | 112 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 59 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 227 | 53 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 223 | 93 |
| Omeprazole | Omeprazole | 218 | 68 |
| Vascepa | Icosapent Ethyl | 217 | 45 |
| Naproxen | Naproxen | 196 | 79 |
| Azelastine Hcl | Azelastine Hcl | 183 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 169 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 167 | 40 |
| Ezetimibe | Ezetimibe | 162 | 45 |
| Cyclosporine | Cyclosporine | 152 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 37 |
| Meclizine Hcl | Meclizine Hcl | 145 | 48 |
| Celecoxib | Celecoxib | 139 | 46 |
| Allopurinol | Allopurinol | 126 | 24 |
| Meloxicam | Meloxicam | 124 | 25 |
| Baclofen | Baclofen | 117 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 42 |
| Gabapentin | Gabapentin | 112 | 30 |
| Azithromycin | Azithromycin | 108 | 63 |
| Pioglitazone Hcl | Pioglitazone Hcl | 107 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 37 |
| Simvastatin | Simvastatin | 103 | 23 |
| Donepezil Hcl | Donepezil Hcl | 100 | 20 |
| Carvedilol | Carvedilol | 99 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 98 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 37 |
| Ketoconazole | Ketoconazole | 91 | 34 |
| Finasteride | Finasteride | 89 | 26 |
| Lisinopril | Lisinopril | 86 | 17 |
| Januvia | Sitagliptin Phosphate | 85 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 16 |
| Hydrocortisone | Hydrocortisone | 79 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 22 |
| Ranolazine Er | Ranolazine | 70 | 16 |
| Fluocinonide-E | Fluocinonide/Emollient Base | 69 | 14 |
| Glimepiride | Glimepiride | 69 | 18 |
| Potassium Chloride | Potassium Chloride | 67 | 20 |
| Prednisone | Prednisone | 67 | 55 |
| Furosemide | Furosemide | 66 | 24 |
| Fluocinonide | Fluocinonide | 64 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 20 |
| Famotidine | Famotidine | 61 | 16 |
| Tramadol Hcl | Tramadol Hcl | 59 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 58 | 24 |
| Dapagliflozin | Dapagliflozin Propanediol | 58 | 12 |
| Metformin Hcl Er | Metformin Hcl | 58 | 13 |
| Tradjenta | Linagliptin | 57 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | suppressed |
| Eliquis | Apixaban | 52 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 16 |
| Irbesartan | Irbesartan | 52 | 12 |
| Ammonium Lactate | Ammonium Lactate | 51 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 33 |
| Glipizide | Glipizide | 50 | suppressed |
| Ibuprofen | Ibuprofen | 50 | 15 |
| Nitroglycerin | Nitroglycerin | 50 | 22 |
| Latanoprost | Latanoprost | 49 | suppressed |
| Lorazepam | Lorazepam | 49 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 12 |
| Prolia | Denosumab | 46 | 28 |
| Sucralfate | Sucralfate | 46 | suppressed |
| Voquezna | Vonoprazan Fumarate | 45 | 20 |
| Lactulose | Lactulose | 44 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | 14 |
| Repatha Sureclick | Evolocumab | 41 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 39 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 38 | 21 |
| Restasis | Cyclosporine | 38 | 18 |
| Atenolol | Atenolol | 36 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | 12 |
| Mometasone Furoate | Mometasone Furoate | 35 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | 18 |
| Creon | Lipase/Protease/Amylase | 33 | 18 |
| Loperamide | Loperamide Hcl | 33 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 23 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Linzess | Linaclotide | 31 | 13 |
| Trazodone Hcl | Trazodone Hcl | 30 | 14 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Ofloxacin | Ofloxacin | 29 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Lubiprostone | Lubiprostone | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 28 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Febuxostat | Febuxostat | 27 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 26 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 12 |
| Ciclopirox | Ciclopirox | 23 | 11 |
| Vemlidy | Tenofovir Alafenamide | 23 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 14 |
| Dutasteride | Dutasteride | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Benzonatate | Benzonatate | 20 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Erythromycin | Erythromycin Base | 19 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Scopolamine | Scopolamine | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 14 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Terconazole | Terconazole | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Ztlido | Lidocaine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,160.80 · 73 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, ENTRESTO, EVENITY, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, MOUNJARO, OTEZLA, OverStitch Endoscopic Suturing System, PREVNAR 20, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VOWST, ZEPBOUND, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error